Posts tagged Jason Flowerday
3DS advances Hodgkin’s lymphoma test

The clinical trial component of 3D Signatures’ (OTCQB:TDSGF; TSXV:DXD; FSE:3D0) Hodgkin's lymphoma test (Telo-HL) validation program is under way. This process is referred to as Stage 3 of the validation program.

Read More
3DS processes first samples from PRECISE trial

3D Signatures (TSXV:DXD; OTCQB:TDSGF; FSE:3D0) has processed and analyzed the first batch of blood samples for the PRECISE prostate cancer trial at its new laboratory and corporate headquarters in the MaRS Discovery District in Toronto.

Read More
3DS names Dr. Kevin Little as CSO

3D Signatures (OTCQB:TDSGF; TSXV:DXD; FSE:3D0) appointed Dr. Kevin Little, a leading biomedical scientist and corporate executive, as its new chief scientific officer, effective immediately.  

Read More
3DS initiates HL validation program

The validation program for 3D Signatures’ (TSX-V:DXD; OTCQB:TDSGF; FSE:3D0) Hodgkin's lymphoma test (Telo-HL) is under way. Telo-HL is powered by the company's TeloView software platform.

Read More
3DS to present positive results for prostate cancer liquid biopsy

Dr. Sabine Mai, a co-founder and principle inventor of 3D Signatures (TSX-V:DXD; OTCQB:TDSGF; FSE:3D0), will present on Feb. 21 at the International Molecular Medicine Tri-Conference in San Francisco, results of a prospective blood-based prostate cancer pilot study using the company’s TeloView software platform.

Read More
3DS begins trading on OTCQB and FSE

Common shares of 3D Signatures (TSX-V:DXD) have started trading on the OTCQB Venture Market in the U.S. under the symbol, TDSGF, and on the Frankfurt Stock Exchange (FSE) in Germany under the symbol, 3D0.

Read More
Jason Flowerday named CEO of 3D Signatures

3D Signatures (TSX-V:DXD) has appointed Jason Flowerday as CEO. He succeeds Ferenc Somogyvari, who will remain on the board.

"Mr. Flowerday is a highly respected biotech entrepreneur with more than 20 years of executive life sciences management and startup experience. He has the entrepreneurial and management skills we need to drive us to commercialization," John Swift, chairman, said in a statement.

Read More